Archived AES Symposia 2005
Presidential Symposium - Behavioral and Cognitive Comorbidities in Pediatric Epilepsy: Recognition, Mechanisms, Assessment, and Treatment
Program Length: 1 hrs 56 min
OverviewThe purpose of this symposium is to provide clinicians and epilepsy care professionals a greater understanding of the behavioral and cognitive problems observed in children with epilepsy. The symposium will begin with a review of recent research findings related to the prevalence and nature of these behavioral and cognitive problems as well as their risk and protective factors. Two presentations will focus on underlying biological mechanisms related to behavioral and cognitive comorbidities. The first will discuss the effects of changes associated with epileptogenesis in the developing brain. The second will address the effects of seizures and antiepileptic drugs (AEDs) on cognition with an emphasis on what is happening at the circuit level. Research findings related to remediation of behavioral and cognitive effects in animals will also be discussed. The final presentation will discuss the complexities of addressing behavioral and cognitive problems in the clinical setting and present guidelines for assessing and treating these problems.
At the conclusion of this activity, participants should be able to:
- Describe common behavioral and cognitive comorbidities found in children with epilepsy
- Understand mechanisms associated with epileptogenesis that might contribute to behavioral and cognitive disruptions in children with new-onset seizures
- Appreciate how seizure-induced and AED-induced cellular and molecular changes may contribute to cognitive and behavioral comorbidities in persons with epilepsy
- Determine which children with epilepsy need behavioral and cognitive assessment and possible referral sources.
Neurologists, psychiatrists, behavioral scientists, nurses, pharmacists, and other healthcare professionals involved in the care of persons with epilepsy.
- Program Chair: Joan K. Austin, D.N.S., RN, FAAN
Joan K. Austin, D.N.S., RN, FAAN
- Behavioral and Cognitive Comorbidities in Children with Epilepsy
David W. Dunn, M.D.
- Effects of Epileptogenesis on Behavior and Cognition
Amy Brooks-Kayal, M.D.
- Seizures and AEDs in the Developing Brain: Therapeutic Strategies
Gregory L. Holmes, M.D.
- Assessment and Treatment of Behavioral and Cognitive Comorbidities in Pediatric Epilepsy
Rochelle Caplan, M.D.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Amy R. Brooks-Kayal, M.D. has indicated she has received consulting fees from the National EpiFellows Advisory Board. Dr. Brooks-Kayal has also indicated she will be referencing unlabeled/unapproved uses of drugs or products in her presentation.
Joan K. Austin, D.N.S., RN, FAAN has indicated she has no real or apparent conflicts of interest to report.
Edward H. Bertram, M.D. (liaison reviewer) has disclosed that he has received salary from Vistagen and is a coinvestigator on an NIH grant. Dr. Bertram has also disclosed that he has received consulting fees from UCB Pharma, Inc.
Rochelle Caplan, M.D. has indicated she has no real or apparent conflicts of interest to report.
David W. Dunn, M.D. has indicated he has received fees for non-CME services from Lilly and Pfizer Inc. and has also contracted research with Lilly, Shire and AstraZeneca.
Gregory L. Holmes, M.D. has indicated he has received consulting fees from UCB Pharma and Novartis. Dr. Holmes has also received fees for non-CME services from UCB Pharma, Novartis and GlaxoSmithKline.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.